Characterization of 9-nitrocamptothecin liposomes: Anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Zheng, Shunzhen ^a   Chang, Shuang ^b   Lu, Jinli ^a   Chen, Zhihui ^a   Xie, Li ^b   Nie, Yu ^b   He, Bin ^b   Zou, Shengquan ^a   Gu, Zhongwei ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSIS INDUCING FACTOR MITOCHONDRION ASSOCIATED 1; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; LIPOSOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RUBITECAN; UNCLASSIFIED DRUG; 9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FATALITY; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PARTICLE SIZE; PROTEIN EXPRESSION; SUSTAINED RELEASE FORMULATION; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; CELL CYCLE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; SOLUBILITY; TUMOR CELL LINE; ULTRASOUND;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG STABILITY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MICE; SOLUBILITY; ULTRASONICS; WATER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958266512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021064     Document Type: Article

References (43)

1. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R, et al. (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-5.
2. You J, Li X, Cui FD, Du YZ, Hong Y, et al. (2008) Folate-conjugated polymer micelles for active targeting to cancer cells: preparation, in vitro evaluation of targeting ability and cytotoxicity. Nanotechnology 19: 102-11.
3. Sezgin Z, Yuksel N, Baykara T, (2007) Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int J Pharm 332: 161-167.
4. Owens DE 3rd, Peppas NA, (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307: 93-102.
5. Cukierman E, Khan DR, (2010) The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 80: 762-70.
6. Unezaki S, Maruyama K, Hosoda JI, Nagae I, Koyanagi Y, et al. (1996) Direct measurement of extravasation of poly-ethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 144: 11-7.
7. Kumagi T, Hiasa Y, Hirschfield GM, (2009) Hepatocellular carcinoma for the non-specialist. BMJ 339: b5039.
8. Padma S, Martinie JB, Iannitti DA, (2009) Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 100: 619-34.
9. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
10. Cha CH, Saif MW, Yamane BH, Weber SM, (2010) Hepatocellular carcinoma: current management. Curr Probl Surg 47: 10-67.
11. Aagaard L, Rossi JJ, (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86.
12. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, et al. (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci US A 95: 4607-12.
13. Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, et al. (2008) Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clinical Cancer Res 14: 4603-11.
14. Maeda H, Sawa T, Konno T, (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74: 47-61.
15. Chan KT, Meng FY, Li Q, Ho CY, Lam TS, et al. (2010) Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 294: 118-24.
16. Nitiss JL, Wang JC, (2006) Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50: 1095-102.
17. Senderowicz AM, (2004) Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16: 670-8.
18. Malumbres M, Barbacid M, (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-41.
19. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-25.
20. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, et al. (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
21. Hochegger H, Takeda S, Hunt T, (2008) Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9: 910-6.
22. Wang JY, Ki SW, (2001) Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 29: 666-73.
23. Zhang Y, Rishi AK, Dawson MI, Tschang R, Farhana L, et al. (2000) S-phase arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid. Cancer Res 60: 2025-32.
24. Vousden KH, (2000) p53: death star. Cell 103: 691-4.
25. Soussi T, (2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 910: 121-37; discussion 137-9.
26. Meeran SM, Katiyar SK, (2008) Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13: 2191-202.
27. Vermeulen K, Van Bockstaele DR, Berneman ZN, (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-49.
28. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-23.
29. Chow DS, Gong L, Wolfe MD, Giovanella BC, (2000) Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Ann N Y Acad Sci 922: 164-74.
30. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, et al. (2004) Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res 21: 2001-8.
31. Koo OM, Rubinstein I, Onyuksel H, (2005) Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1: 77-84.
32. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-84.
33. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, et al. (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95: 4607-12.
34. Gabizon AA, (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7: 223-5.
35. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, et al. (2006) Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12: 2607-12.
36. Rivera E, (2003) Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8 (Suppl 2): 3-9.
37. Khan DR, Rezler EM, Lauer-Fields J, Fields GB, (2008) Effects of drug hydrophobicity on liposomal stability. Chem Biol Drug Des 71: 3-7.
38. Alexis F, Pridgen EM, Langer R, Farokhzad OC, (2010) Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 197 (Part 1): 55-86.
39. Malam Y, Loizidou M, Seifalian AM, (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30: 592-9.
40. Chen J, Ping QN, Guo JX, Chu XZ, Song MM, (2006) Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 32: 719-26.
41. Stähler F, Roemer K, (1998) Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 17: 3507-12.
42. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, et al. (1993) Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7: 1407-13.
43. Anand S, Honari G, Hasan T, Elson P, Maytin EV, (2009) Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 15: 3333-43.